Want to see GB:IKA full AI Analyst Report?
Top Page
Ilika plc
(LSE:IKA)
Select Model
Select Model
Rating:45Neutral
Price Target:
26.00 p
▼(-3.70% Downside)
Action:Reiterated
Date:08/03/26
The score is held down primarily by weak financial performance (ongoing losses, negative margins, and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). The earnings call adds some support via tangible commercialization and partnership progress, but modest revenue and widening losses keep execution and funding risks elevated; valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
Strong IP and technical advantages
A broad patent estate (88 granted patents) and demonstrable technical benefits (weight, charge time, safety) create durable barriers to entry and licensing leverage. This strengthens long-term monetisation potential via licences, royalties and partner integrations across multiple end markets.
Negative Factors
Persistent losses and negative margins
Sustained negative gross profit and widening operating losses indicate the business has not yet proven a scalable, profitable model. Over months this pressure requires ongoing funding, reduces reinvestment capacity, and risks shareholder dilution if profitability is not achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong IP and technical advantages
A broad patent estate (88 granted patents) and demonstrable technical benefits (weight, charge time, safety) create durable barriers to entry and licensing leverage. This strengthens long-term monetisation potential via licences, royalties and partner integrations across multiple end markets.
Read all positive factors
Ilika plc (IKA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£49.72M
Dividend YieldN/A
Average Volume (3M)276.55K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth53.47%
EPS Growth-14.16%
CountryUK
Employees68
SectorIndustrials
Sector Strength72
IndustryElectrical Equipment & Parts
Share Statistics
EPS (TTM)-0.04
Shares Outstanding198,889,310
10 Day Avg. Volume178,456
30 Day Avg. Volume276,546
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)4.11
Price to Sales (P/S)526.11
P/FCF Ratio-11.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£2.00M
Ilika plc Business Overview & Revenue Model
Company Description
Ilika plc, an enterprise established in 2004 with its headquarters in Romsey, United Kingdom, focuses on the conception, refinement, and commercial production of solid-state battery technology. These advanced power cells are distributed globally u...
How the Company Makes Money
Ilika primarily makes money through (1) contract and grant-funded R&D and (2) commercialisation of its solid-state battery technology, including licensing and related agreements. Revenue can include payments for development services performed for ...
Ilika plc Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Jan 28, 2027
Earnings Call Sentiment Neutral
The call presented meaningful technical and commercial progress: first Stereax revenues, manufacturing partnerships (Cirtec), automated pilot line, positive prototype feedback from OEMs, defense and Brompton collaborations, and continued grant support. However, financials remain an important constraint — revenue is still modest, EBITDA losses widened (~19% year‑on‑year), loss per share increased (~14.9%), and pilot capacity and resource limitations constrain immediate scale‑up. There is clear momentum on the technology and validation front but material execution, funding and timing risks remain.Positive Updates
Revenue Commencement from Stereax and Stable FY Revenue
Reported revenue was GBP 1.1m for FY2026, broadly flat year‑on‑year (0% change). For the first time Ilika recognized commercial revenue from Stereax wafer/electrode sales (GBP 100k), marking the transition from R&D to revenue-generating activity (approximately 9.1% of reported revenue). Management expects this to build through the current financial year.
Negative Updates
Revenue Still Very Modest and Concentrated
Although revenue was stable at GBP 1.1m, commercial revenues are still small: Stereax electrode sales were only GBP 100k in the year (≈9.1% of revenue) and the business remains early stage in commercial traction versus expectations for scale.
Read all updates
Q4-2026 Updates
Positive
Negative
Revenue Commencement from Stereax and Stable FY Revenue
Reported revenue was GBP 1.1m for FY2026, broadly flat year‑on‑year (0% change). For the first time Ilika recognized commercial revenue from Stereax wafer/electrode sales (GBP 100k), marking the transition from R&D to revenue-generating activity (approximately 9.1% of reported revenue). Management expects this to build through the current financial year.
Read all positive updates
Company Guidance
Management guided that Ilika is transitioning to revenue generation across two product lines (Goliath large‑format and Stereax miniature) and gave detailed metrics: FY2026 revenue was £1.1m (flat YoY) including £0.1m of electrode sales to Cirtec, grant income ~£1.0m, EBITDA loss £6.2m (vs £5.2m prior) and loss per share 4.02p (vs 3.50p), year‑end cash £5.3m (plus a July top‑up raise), 88 granted patents, pilot‑line capacity ~1.5 MWh/yr (c.20,000 10Ah cells/yr), 16 Stereax customers with 19 orders, commenced M300 deliveries, shipped 10A Goliath prototypes and are converting those into a 10A MVP with early non‑automotive commercial opportunities (defence, e‑bikes/Brompton) and expected further grant support leading to option‑to‑license milestones; modeling with Balance indicated a c.20% weight (and range) benefit and a 1/3 reduction in charge time (18→12 minutes) for Goliath in a Hyundai Ioniq 5.Ilika plc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 112.80K | 73.50K | 20.10K | 33.85K | 30.88K |
| Gross Profit | -2.55M | -452.70K | -1.06M | -1.97M | -1.49M |
| EBITDA | -7.82M | -5.38M | -4.00M | -7.30M | -6.81M |
| Net Income | -7.24M | -5.90M | -4.81M | -7.30M | -7.13M |
Balance Sheet | |||||
| Total Assets | 16.77M | 19.45M | 22.83M | 26.91M | 33.93M |
| Cash, Cash Equivalents and Short-Term Investments | 5.35M | 7.98M | 11.95M | 15.87M | 23.45M |
| Total Debt | 1.08M | 470.70K | 625.30K | 618.48K | 847.60K |
| Total Liabilities | 2.35M | 2.27M | 2.47M | 2.14M | 2.50M |
| Stockholders Equity | 14.42M | 17.18M | 20.36M | 24.77M | 31.44M |
Cash Flow | |||||
| Free Cash Flow | -5.36M | -6.28M | -4.13M | -7.45M | -10.08M |
| Operating Cash Flow | -4.70M | -4.18M | -2.46M | -6.05M | -5.64M |
| Investing Cash Flow | -1.48M | 2.47M | -5.06M | -1.40M | -4.44M |
| Financing Cash Flow | 3.55M | 1.93M | -316.70K | -75.78K | 23.71M |
Ilika plc Technical Analysis
Negative
27.00
Price Trends
27.17
Negative
30.48
Negative
32.00
Negative
Market Momentum
-0.45
Negative
37.06
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IKA, the sentiment is Negative. The current price of 27 is above the 20-day moving average (MA) of 25.72, below the 50-day MA of 27.17, and below the 200-day MA of 32.00, indicating a bearish trend. The MACD of -0.45 indicates Negative momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IKA.
Ilika plc Risk Analysis
Ilika plc disclosed 6 risk factors in its most recent earnings report. Ilika plc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ilika plc Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £1.10B | 23.44 | 15.29% | 0.79% | 8.85% | 29.67% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
55 Neutral | £507.01M | -57.61 | -4.89% | 0.04% | -1.21% | 46.27% | |
52 Neutral | £39.00M | -5.40 | -42.23% | ― | ― | 42.60% | |
49 Neutral | £857.87M | -16.72 | -39.26% | ― | -37.09% | -67.49% | |
45 Neutral | £49.72M | -6.20 | -45.06% | ― | 53.47% | -14.16% |
* Industrials Sector Average
GB:IKA
Ilika plc
25.00
-11.00
-30.56%
GB:CWR
Ceres Power Holdings
401.20
297.10
285.40%
GB:VLX
Volex plc
607.00
272.78
81.61%
GB:XPP
XP Power
1,810.00
921.00
103.60%
GB:GELN
Gelion PLC
17.00
-3.00
-15.00%
Ilika plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Ilika ramps solid state battery commercialisation as losses widen
Positive
Jul 29, 2026
Ilika has reported full-year results showing it has moved its Stereax solid state batteries into commercial production with manufacturing partner Cirtec Medical, delivering M300 prototypes and commercial-grade electrodes to a portfolio of 16 medic...
Business Operations and StrategyPrivate Placements and Financing
Ilika Raises £5m to Drive Commercial Roll-Out of Solid-State Battery Lines
Positive
Jul 7, 2026
Ilika plc has completed an oversubscribed retail offer, raising around £0.5 million through the issue of 1,785,714 new shares at 28 pence, as part of a wider capital raise. Together with placing and director subscription shares, the company i...
Business Operations and StrategyPrivate Placements and Financing
Ilika launches retail offer to fund Stereax roll-out and Goliath development
Positive
Jul 3, 2026
Ilika plc has launched a retail offer to raise up to £0.5 million via BookBuild, issuing up to 1,785,714 new ordinary shares at 28 pence each, alongside a previously announced £4.56 million placing and director subscription at the same p...
Business Operations and StrategyPrivate Placements and Financing
Ilika raises £4.56m to accelerate solid-state battery commercialisation
Positive
Jul 3, 2026
Ilika plc, the AIM-listed solid-state battery specialist, is deepening its push into miniaturised medical and EV power solutions through its Stereax and Goliath product lines. The company commercialises its technology via licensing agreements with...
Business Operations and StrategyPrivate Placements and Financing
Ilika launches £5m fundraise to accelerate solid-state battery commercialisation
Positive
Jul 2, 2026
Ilika plc has launched a capital raising of up to approximately £5.0 million through a placing of up to 16,000,000 new shares, a retail offer to UK investors and direct subscriptions by directors at an issue price of 28 pence per share. The p...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Ilika Begins Stereax Revenues as Goliath Solid-State Batteries Gain Traction
Positive
May 21, 2026
Ilika has begun generating its first commercial revenues from its Stereax miniature batteries through a manufacturing licence with Cirtec Medical, marking a key commercialisation milestone as electrodes produced in the UK are now being supplied to...
Business Operations and StrategyFinancial Disclosures
Ilika Marks First Stereax Revenues as Goliath Batteries Gain Traction in Defence and E-Bikes
Positive
May 21, 2026
Ilika plc, a UK developer of solid-state batteries, focuses on next-generation power solutions for electric vehicles, medical implants, industrial sensors and consumer appliances. Its portfolio centres on Stereax micro-batteries and Goliath large-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.